Coeptis Expands Cancer Treatment Capabilities with GEAR Subsidiary Coeptis Therapeutics has launched GEAR Therapeutics to advance its GEAR cell therapy platform, which modifies natural killer cells to improve cancer treatment. The technology, licensed from VyGen-Bio, aims to optimize antibody-based therapies, particularly for multiple myeloma. This move positions Coeptis for significant growth in precision immuno-oncology.12